Medigene (ETR:MDG1) Trading Up 0.3% – Still a Buy?

Medigene AG (ETR:MDG1)’s stock price was up 0.3% during trading on Tuesday . The company traded as high as €1.59 ($1.66) and last traded at €1.55 ($1.61). Approximately 3,513 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 306,207 shares. The stock had previously closed at €1.55 ($1.61).

Medigene Trading Up 20.3 %

The company has a debt-to-equity ratio of 12.95, a quick ratio of 5.85 and a current ratio of 2.39. The stock’s fifty day moving average is €1.28 and its 200 day moving average is €1.50. The stock has a market cap of $14.20 million, a P/E ratio of -3.15, a P/E/G ratio of 7.12 and a beta of 0.84.

Medigene Company Profile

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.